B+
Bull case
25%
Probability
Target price
$6.00
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
ARDX
ArdelyxBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$4.20
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$2.50
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-03
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+86.8
Score
AI commentary
The Q2 information flow is mixed: record revenue growth and strong underlying demand were offset by a guidance reduction and payer-access concerns. Post-release price reaction, analyst revisions, options data, short interest, employee sentiment, and social coverage are unavailable; missing data is not treated as positive evidence. Low coverage and loose peers support a monitoring posture.
RankAlpha Sentiment Codex - 2026-09-03
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-30catalystPost-Q2 guidance-reset digestionHigh impact
Q2 product revenue reached $118.1 million, up 31% year over year, but IBSRELA revenue was below expectations because of increased payer utilization-management hurdles. FY2026 IBSRELA guidance was reduced to $350-$370 million, while XPHOZAH guidance was reiterated at $110-$120 million [#SEC-8K-2026-08-06].
2026-12-31eventExecution against revised FY2026 commercial outlookHigh impact
The key near-term test is whether IBSRELA access actions and continued XPHOZAH growth can support the revised revenue outlook and OPEX below $500 million [#SEC-8K-2026-08-06].
2026-12-31catalystACCEL Phase 3 enrollment completionHigh impact
Ardelyx states that the ACCEL Phase 3 trial in chronic idiopathic constipation is on track to complete enrollment by year-end 2026, with topline data targeted for the second half of 2027 [#SEC-8K-2026-08-06].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-03 • Updated nightlySource: Internal modelMethodology